JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB32561

Anti-Cleaved PARP1 antibody [Y34]

  • RabMAb
  • Recombinant
  • KO Validated
  • Lab Essentials
  • 20ul selling size
  • What is this?

5

(1 Review)

|

(86 Publications)

Rabbit Recombinant Monoclonal PARP1 antibody. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 86 publications.

View Alternative Names

ADPRT, PPOL, PARP1, Poly [ADP-ribose] polymerase 1, PARP-1, ADP-ribosyltransferase diphtheria toxin-like 1, DNA ADP-ribosyltransferase PARP1, NAD(+) ADP-ribosyltransferase 1, Poly[ADP-ribose] synthase 1, Protein poly-ADP-ribosyltransferase PARP1, ARTD1, ADPRT 1

4 Images
Flow Cytometry (Intracellular) - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
  • Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-Cleaved PARP1 antibody [Y34] (AB32561)

Primary ab 1/50 dilution (0.5μg / Red). Secondary abGoat anti rabbit IgG (FITC). Secondary ab concentration 1/150 dilution. Cell line Jurkat (human acute T cell leukemia) treated with (Right) or without (Left) 4μM Camptothecin for 5h. Fixative 4% paraformaldehyde. Datasheet comment Intracellular flow cytometric analysis of apoptotic and non-apoptotic Jurkat cells using anti-cleaved PARP1 RabMAb (ab32561). Jurkat cells were either left untreated (A) or treated with camptothecin (4 uM, 5 hr) to induce apoptosis (B). Cells were fixed and permeabilized , and then stained with anti-cleaved PARP1. The results indicate that 43% of cells were positive for cleaved PARP1 (B, M2) after treatment, compared to 9% positive without treatment (A, M2).

Immunoprecipitation - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
  • IP

Lab

Immunoprecipitation - Anti-Cleaved PARP1 antibody [Y34] (AB32561)

Purified ab32561 at 1/50 dilution (2μg) immunoprecipitating Cleaved PARP1 in HeLa whole cell lysate.
Lane 1 (input) : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab32561 + HeLa whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab32561 in HeLa whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 85 kDa

All lanes:

Immunoprecipitation - Anti-Cleaved PARP1 antibody [Y34] (ab32561)

Predicted band size: 113 kDa

false

Western blot - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
  • WB

Lab

Western blot - Anti-Cleaved PARP1 antibody [Y34] (AB32561)

Lane 1 : Wild type HAP1 (untreated) whole cell lysate (20 μg)
Lane 2 : PARP1 (untreated) knockout HAP1 (untreated) whole cell lysate (20 μg)
Lane 3 : HeLa (untreated) whole cell lysate (20 μg)
Lane 4 : HAP1 (staurosporin treated, 1 u M, 4 hr) whole cell lysate (20 μg)
Lane 5 : PARP1 (staurosporin treated, 1 uM, 4 hr) knockout HAP1 whole cell lysate (20 μg)
Lane 6 : HeLa (staurosporin treated, 1 uM, 4 hr) whole cell lysate (20 μg)

Lanes 1 - 6 : Merged signal (red and green). Green - ab32561 observed at 100 kDa. Red - loading control, ab8245, observed at 37 kDa.

ab32561 was shown to specifically react with PARP1 (untreated) when PARP1 (untreated) knockout samples were used. Wild-type and PARP1 (untreated) knockout samples were subjected to SDS-PAGE. ab32561 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Cleaved PARP1 antibody [Y34] (ab32561)

Predicted band size: 113 kDa

false

Western blot - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
  • WB

Unknown

Western blot - Anti-Cleaved PARP1 antibody [Y34] (AB32561)

All lanes:

Western blot - Anti-Cleaved PARP1 antibody [Y34] (ab32561) at 1/1000 dilution

Lane 1:

Un-treated Jurkat cell lysate.

Lane 2:

Jurkat cell lysate treated with Camptothecin.

Predicted band size: 113 kDa

Observed band size: 85 kDa

false

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Cleaved PARP1 antibody [Y34]

  • HRP

    HRP Anti-Cleaved PARP1 antibody [Y34]

  • Carrier free

    Anti-Cleaved PARP1 antibody [Y34] - BSA and Azide free

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Cleaved PARP1 antibody [Y34]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

Y34

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

Flow Cyt (Intra), IP, WB, ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

This antibody is specific for p85 cleaved form of PARP1.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/50", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/50", "FlowCytIntra-species-notes": "<p><a href='/en-us/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>" } } }

Product details

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS, 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cleaved PARP1 also known as cPARP is a fragment of the PARP1 protein an important DNA repair enzyme. The full PARP1 protein has a molecular weight of approximately 116 kDa but after cleavage during apoptosis the cleaved PARP1 fragments typically have a molecular weight of around 89 kDa and 24 kDa. PARP1 is expressed abundantly in the cell nucleus where it plays important roles in maintaining genomic integrity. The cleavage of PARP1 is a common marker for cell apoptosis pointing towards its breakdown in response to cellular stress.
Biological function summary

The enzymatic function of PARP1 involves the transfer of ADP-ribose units from NAD+ to target proteins a process known as ADP-ribosylation. PARP1 operates as a part of the base excision repair complex essential in DNA repair processes. The cleaved form of PARP1 no longer facilitates DNA repair marking a shift towards apoptosis. When PARP1 is cleaved it indicates caspase activity implying cells are undergoing programmed cell death.

Pathways

Cleaved PARP1 is deeply involved in the apoptosis and DNA damage response pathways. In the apoptosis pathway PARP1 interacts with key proteins like caspase-3 which cleaves PARP during apoptosis. In the DNA damage response PARP1 collaborates with proteins such as XRCC1 facilitating the base excision repair pathway important for fixing single-strand DNA breaks. These pathways highlight the dual role of PARP1 in promoting cell survival through repair and cell death via apoptosis.

Cleaved PARP1 serves as an important marker in cancer and neurodegenerative diseases. In cancer research elevated levels of cleaved PARP1 suggest increased rates of apoptosis in response to anti-cancer therapies linking it to tumor suppression efforts. In neurodegenerative diseases excessive activation and cleavage of PARP1 can result in cell death exacerbating conditions like Alzheimer's disease. Through these contexts cleaved PARP1 connects to other therapeutic targets such as caspase proteins in cancer and to potential PARP inhibitors in neurodegenerative disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair (PubMed : 17177976, PubMed : 18055453, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 20388712, PubMed : 21680843, PubMed : 22582261, PubMed : 23230272, PubMed : 25043379, PubMed : 26344098, PubMed : 26626479, PubMed : 26626480, PubMed : 30104678, PubMed : 31796734, PubMed : 32028527, PubMed : 32241924, PubMed : 32358582, PubMed : 33186521, PubMed : 34465625, PubMed : 34737271). Mediates glutamate, aspartate, serine, histidine or tyrosine ADP-ribosylation of proteins : the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units (PubMed : 19764761, PubMed : 25043379, PubMed : 28190768, PubMed : 29954836, PubMed : 35393539, PubMed : 7852410, PubMed : 9315851). Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage (PubMed : 33186521, PubMed : 34874266). Specificity for the different amino acids is conferred by interacting factors, such as HPF1 and NMNAT1 (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Following interaction with HPF1, catalyzes serine ADP-ribosylation of target proteins; HPF1 confers serine specificity by completing the PARP1 active site (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Also catalyzes tyrosine ADP-ribosylation of target proteins following interaction with HPF1 (PubMed : 29954836, PubMed : 30257210). Following interaction with NMNAT1, catalyzes glutamate and aspartate ADP-ribosylation of target proteins; NMNAT1 confers glutamate and aspartate specificity (By similarity). PARP1 initiates the repair of DNA breaks : recognizes and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones (H2BS6ADPr and H3S10ADPr), thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks (PubMed : 17177976, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 23230272, PubMed : 27067600, PubMed : 34465625, PubMed : 34874266). HPF1 initiates serine ADP-ribosylation but restricts the polymerase activity of PARP1 in order to limit the length of poly-ADP-ribose chains (PubMed : 33683197, PubMed : 34732825, PubMed : 34795260). In addition to base excision repair (BER) pathway, also involved in double-strand breaks (DSBs) repair : together with TIMELESS, accumulates at DNA damage sites and promotes homologous recombination repair by mediating poly-ADP-ribosylation (PubMed : 26344098, PubMed : 30356214). Mediates the poly-ADP-ribosylation of a number of proteins, including itself, APLF, CHFR, RPA1 and NFAT5 (PubMed : 17396150, PubMed : 19764761, PubMed : 24906880, PubMed : 34049076). In addition to proteins, also able to ADP-ribosylate DNA : catalyzes ADP-ribosylation of DNA strand break termini containing terminal phosphates and a 2'-OH group in single- and double-stranded DNA, respectively (PubMed : 27471034). Required for PARP9 and DTX3L recruitment to DNA damage sites (PubMed : 23230272). PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites (PubMed : 23230272). PARP1-mediated DNA repair in neurons plays a role in sleep : senses DNA damage in neurons and promotes sleep, facilitating efficient DNA repair (By similarity). In addition to DNA repair, also involved in other processes, such as transcription regulation, programmed cell death, membrane repair, adipogenesis and innate immunity (PubMed : 15607977, PubMed : 17177976, PubMed : 19344625, PubMed : 27256882, PubMed : 32315358, PubMed : 32844745, PubMed : 35124853, PubMed : 35393539, PubMed : 35460603). Acts as a repressor of transcription : binds to nucleosomes and modulates chromatin structure in a manner similar to histone H1, thereby altering RNA polymerase II (PubMed : 15607977, PubMed : 22464733). Acts both as a positive and negative regulator of transcription elongation, depending on the context (PubMed : 27256882, PubMed : 35393539). Acts as a positive regulator of transcription elongation by mediating poly-ADP-ribosylation of NELFE, preventing RNA-binding activity of NELFE and relieving transcription pausing (PubMed : 27256882). Acts as a negative regulator of transcription elongation in response to DNA damage by catalyzing poly-ADP-ribosylation of CCNT1, disrupting the phase separation activity of CCNT1 and subsequent activation of CDK9 (PubMed : 35393539). Involved in replication fork progression following interaction with CARM1 : mediates poly-ADP-ribosylation at replication forks, slowing fork progression (PubMed : 33412112). Poly-ADP-ribose chains generated by PARP1 also play a role in poly-ADP-ribose-dependent cell death, a process named parthanatos (By similarity). Also acts as a negative regulator of the cGAS-STING pathway (PubMed : 32315358, PubMed : 32844745, PubMed : 35460603). Acts by mediating poly-ADP-ribosylation of CGAS : PARP1 translocates into the cytosol following phosphorylation by PRKDC and catalyzes poly-ADP-ribosylation and inactivation of CGAS (PubMed : 35460603). Acts as a negative regulator of adipogenesis : catalyzes poly-ADP-ribosylation of histone H2B on 'Glu-35' (H2BE35ADPr) following interaction with NMNAT1, inhibiting phosphorylation of H2B at 'Ser-36' (H2BS36ph), thereby blocking expression of pro-adipogenetic genes (By similarity). Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5 (PubMed : 27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed : 27257257).. Poly [ADP-ribose] polymerase 1, processed C-terminus. Promotes AIFM1-mediated apoptosis (PubMed : 33168626). This form, which translocates into the cytoplasm following cleavage by caspase-3 (CASP3) and caspase-7 (CASP7) in response to apoptosis, is auto-poly-ADP-ribosylated and serves as a poly-ADP-ribose carrier to induce AIFM1-mediated apoptosis (PubMed : 33168626).. Poly [ADP-ribose] polymerase 1, processed N-terminus. This cleavage form irreversibly binds to DNA breaks and interferes with DNA repair, promoting DNA damage-induced apoptosis.
See full target information PARP1

Publications (86)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 15:19695 PubMed40467837

2025

Radiosensitizing effects of Withaferin A in gastric cancer cells via autophagy Inhibition and mitochondrial disruption.

Applications

Unspecified application

Species

Unspecified reactive species

Ping Lu,Juan Xue,Xuemeng Ji

Clinical & experimental metastasis 42:12 PubMed39856383

2025

Repurposing neuroleptics: clozapine as a novel, adjuvant therapy for melanoma brain metastases.

Applications

Unspecified application

Species

Unspecified reactive species

Tobias Wikerholmen,Erlend Moen Taule,Emma Rigg,Birgitte Feginn Berle,Magnus Sættem,Katharina Sarnow,Halala Sdik Saed,Terje Sundstrøm,Frits Thorsen

Journal of translational medicine 22:889 PubMed39358756

2024

Establishment and characterization of 18 Sarcoma Cell Lines: Unraveling the Molecular Mechanisms of Doxorubicin Resistance in Sarcoma Cell Lines.

Applications

Unspecified application

Species

Unspecified reactive species

Young-Eun Cho,Soon-Chan Kim,Ha Jeong Kim,Ilkyu Han,Ja-Lok Ku

International journal of molecular sciences 25: PubMed38892310

2024

Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 Regulation.

Applications

Unspecified application

Species

Unspecified reactive species

Mi-Ri Kwon,Ji-Soo Park,Eun-Jung Ko,Jin Park,Eun-Jin Ju,Seol-Hwa Shin,Ga-Won Son,Hye-Won Lee,Yun-Yong Park,Myoung-Hee Kang,Yeon-Joo Kim,Byeong-Moon Kim,Hee-Jin Lee,Tae-Won Kim,Chong-Jai Kim,Si-Yeol Song,Seok-Soon Park,Seong-Yun Jeong

Heliyon 10:e23831 PubMed38332874

2024

Retinoblastoma vulnerability to combined and salvage pyrimidine ribonucleotide synthesis pharmacologic blockage.

Applications

Unspecified application

Species

Unspecified reactive species

Tanzina Mollick,Suhas Darekar,Basile Dalarun,Flavia Plastino,Juan Zhang,Andres Pastor Fernández,Twana Alkasalias,Helder André,Sonia Laín

Heliyon 9:e23079 PubMed38144346

2023

Ursolic acid induces apoptosis and pyroptosis in Reh cells by upregulating of the JNK signalling pathway based on network pharmacology and experimental validation.

Applications

Unspecified application

Species

Unspecified reactive species

Ying Luo,Jing Xiang,Shuangyang Tang,Shiting Huang,Yishan Zhou,Haiyan Shen

Cell death & disease 14:347 PubMed37268653

2023

SLC43A2 and NFκB signaling pathway regulate methionine/cystine restriction-induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop.

Applications

Unspecified application

Species

Unspecified reactive species

Hao Peng,Yuyu Yan,Min He,Jinxia Li,Lianghai Wang,Wei Jia,Lan Yang,Jinfang Jiang,Yunzhao Chen,Feng Li,Xianglin Yuan,Lijuan Pang

Bioscience trends 17:136-147 PubMed36823043

2023

FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.

Applications

Unspecified application

Species

Unspecified reactive species

Zhengxia Wang,Junyi Shen,Chuwen Chen,Tianfu Wen,Chuan Li

Journal of oncology 2022:8545441 PubMed36317123

2022

IMP4 Silencing Inhibits the Malignancy of Lung Adenocarcinoma via ERK Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Ruzhen Li,Zhaohui Han,Wei Ma,Lin Zhang,Xiangwei Zhang,Yuanzhu Jiang,Wei Dong

Experimental and therapeutic medicine 24:706 PubMed36382092

2022

Geniposide inhibits cell proliferation and migration in human oral squamous carcinoma cells via AMPK and JNK signaling pathways.

Applications

Unspecified application

Species

Unspecified reactive species

Guohui Bai,Bin Chen,Xin Xiao,Yuexin Li,Xia Liu,Dan Zhao,Lei Zhang,Degang Zhao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com